Scarica l'app Stockscreener
48.53
0.21%
-0.10
Dopo l'orario di chiusura:
48.53
Precedente Chiudi:
$48.63
Aprire:
$48.97
Volume 24 ore:
442.30K
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.45B
Reddito:
$232.39M
Utile/perdita netta:
$-26.79M
Rapporto P/E:
-44.92
EPS:
-1.0804
Flusso di cassa netto:
$4.41M
1 W Prestazione:
-4.84%
1M Prestazione:
-13.09%
6M Prestazione:
-15.86%
1 anno Prestazione:
+54.85%
Intervallo 1D:
$48.28
$49.83
Intervallo di 1 settimana:
$48.13
$52.02
Portata 52W:
$29.48
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
48.53 | 1.52B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Director Hollings C. Renton plans to sell 5,000 AnaptysBio (ANAB) shares valued at about $249K. - Stock Titan
ANAB Maintained by JP Morgan -- Price Target Lowered to $60.00 - GuruFocus
JPMorgan Chase & Co. Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $60.00 - MarketBeat
Is AnaptysBio (ANAB) Cheap On Its Royalty Story Despite Tax Driven Earnings? - Simply Wall Street
AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Stock Bumped Up to Buy by Wall Street Zen - MarketBeat
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? - Insider Monkey
How Return To Profit Will Impact AnaptysBio (ANAB) Investors - simplywall.st
ANAB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
Q3 Earnings Estimate for AnaptysBio Issued By HC Wainwright - MarketBeat
ANAB Maintained by Leerink Partners -- Price Target Lowered to $81 - GuruFocus
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $81 - Moomoo
Leerink Partners Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
Leerink Partners maintains Outperform rating on AnaptysBio, $81 price target - TradingView
AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines - Simply Wall Street
Bank of America Corp DE Makes New $28.20 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio earnings analysis: questions answered and next catalysts By Investing.com - Investing.com Nigeria
AnaptysBio earnings analysis: questions answered and next catalysts - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%What's Next? - MarketBeat
AnaptysBio, Inc. (0HFQ.L) latest press releases and corporate news - Yahoo Finance UK
AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c - StreetInsider
Why is AnaptysBio stock rising afterhours today? - Investing.com
Why is AnaptysBio stock rising afterhours today? By Investing.com - Investing.com India
AnaptysBio Net Income Jumps to $177.3 Million on $181.5 Million Tax Benefit - Minichart
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio Inc (ANAB) Q2 Revenue Beats Estimates; Price-to-Sales Ratio Signals High Growth Expectations - GuruFocus
AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours - marketscreener.com
Anaptys Q2FY26 Results: Net profit jumps on $181.5m tax benefit - scanx.trade
AnaptysBio : Annual Transition Report (Form 10-KT) - marketscreener.com
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties - TradingView
Spin-off leaves AnaptysBio (ANAB) a lean royalty firm - Stock Titan
AnaptysBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring A Potential 62.78% Upside - DirectorsTalk Interviews
AnaptysBio (ANAB) director adds shares as RSUs vest - Stock Titan
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Nigeria
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - moomoo.com
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Orwin John A | Director |
Sep 15 '26 |
Option Exercise |
0.00 |
1,300 |
0 |
17,995 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):